<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00930215</url>
  </required_header>
  <id_info>
    <org_study_id>D961HC00008</org_study_id>
    <nct_id>NCT00930215</nct_id>
  </id_info>
  <brief_title>Study Comparing Gelatine Capsule 40 mg D961H and HPMC Capsule in Japanese Healthy Males</brief_title>
  <official_title>Open Label, Randomized, Single Center, 2-way Crossover Bioequivalence Study Comparing Gelatine Capsule 40 mg D961H and HPMC Capsule 40 mg D961H After Repeated Oral Administration in Japanese Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether the HPMC capsule of D961H 40 mg is
      bioequivalent to gelatine capsules of D961H 40 mg after a steady state is reached on Day 5
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirm the HPMC capsule of D961H 40 mg is bioequivalent to the gelatin capsule of D961H 40 mg by assessment of area under the plasma concentration-time curve at steady state on Day 5</measure>
    <time_frame>PK sample at Day 5 of treatment period 1 and treatment period 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the PK properties of HPMC capsule of D961H 40 mg following repeated oral doses, by assessment of plasma concentrations, mean residence time, time to maximum plasma concentration and half-life on Day 5</measure>
    <time_frame>PK sample on Day 5 of treatment period 1 and treatment period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety and tolerability of HPMC capsule of D961H 40 mg by assessment of AEs, clinical lab tests, ECG, vital signs.</measure>
    <time_frame>Pre-entry, Day 5 of treatment period 1 and treatment period 2 and follow up (5-7 days after last dose)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>D961H 40 mg gelatin capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 way crossover</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D961H 40 mg HPMC capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 way crossover</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D961H</intervention_name>
    <description>Oral gelatin capsule</description>
    <arm_group_label>D961H 40 mg gelatin capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D961H</intervention_name>
    <description>Oral HPMC capsule</description>
    <arm_group_label>D961H 40 mg HPMC capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Japanese

          -  Classified as homo-EM

          -  Negative for HIV, Hepatitis B, Hepatitis C and syphilis

        Exclusion Criteria:

          -  Significant clinical illness from 2 weeks preceding the pre-entry visit to the
             randomization

          -  Past or present cardiac, renal, hepatic, neurological or gastrointestinal disease
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takenobu Masaoka</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Masataka Date</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca KK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shunji Matsuki</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyushu Clinical Pharmacology Research Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2009</study_first_submitted>
  <study_first_submitted_qc>June 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2009</study_first_posted>
  <last_update_submitted>September 9, 2009</last_update_submitted>
  <last_update_submitted_qc>September 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Healthy volunteer</keyword>
  <keyword>Japanese males</keyword>
  <keyword>homo-EM</keyword>
  <keyword>Bioequivalence study</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

